Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Soliqua 100/33?

Soliqua 100/33 (Insulin glargine/lispro, 3:1 premixed)

Soliqua is a once‑daily premixed insulin used for the treatment of type 2 diabetes mellitus. The 100/33 strength contains 100 units of insulin glargine (long‑acting) and 33 units of insulin lispro (rapid‑acting) in a 3:1 ratio.

Feature Details
Intended Use Basal‑bolus replacement therapy for type 2 diabetes when oral agents or basal insulin alone are insufficient.
Typical Starting Dose 0.2–0.4 units/kg body weight, divided 70 % basal (glargine) and 30 % bolus (lispro).
Administration Subcutaneous injection once daily, usually at the same time each day. Common sites: abdomen, thigh, or upper arm.
Timing Can be given in the evening or early morning; insulin lispro is meant to cover meals, so it should be administered within 30 minutes before or after eating.
Monitoring Blood glucose at least twice daily (fasting and post‑meal). Adjust dose based on glucose patterns and HbA1c.
Typical Dose Range 20–80 units/day, but varies widely; titration is individualized.
Common Adverse Effects Hypoglycaemia (most common), injection‑site reactions (pain, redness, swelling).
Less Common Edema, weight gain, rare allergic reactions.
Contraindications Hypersensitivity to any component of Soliqua, type 1 diabetes (unless used as part of a basal‑bolus regimen under specialist care).
Warnings & Precautions • Use with caution in renal or hepatic impairment.
• Monitor for hypoglycaemia in elderly, patients with reduced food intake, or those on other hypoglycaemic agents.
• Pregnancy: insulin is the preferred agent; use as directed by a healthcare provider.
Drug Interactions • Caffeine and alcohol can blunt hypoglycaemic effect.
• Other antidiabetic agents may increase hypoglycaemia risk.
Storage Store in refrigerator (2–8 °C). After first use, can be kept at room temperature (up to 30 °C) for up to 28 days. Protect from light.
Disposal Follow local regulations for sharps; use puncture‑resistant containers.
Patient Education Points 1. Check blood glucose before the first dose each day.
2. Watch for symptoms of low or high blood sugar (sweating, shakiness, confusion, blurred vision, or extreme thirst and urination).
3. Rotate injection sites to avoid lipodystrophy.
4. Keep a log of doses, meals, and glucose readings.

Quick Tips for Patients

  • Consistency matters – inject at the same time and at a regular interval each day.
  • Meal timing – if you take Soliqua with a meal, administer the lispro part just before or after eating; the glargine part gives basal coverage throughout the day.
  • Hypoglycaemia management – carry a fast‑acting carbohydrate (glucose tablets, fruit juice). Treat promptly and then follow with a snack if necessary.
  • Watch for injection‑site changes – if you notice hard lumps (lipohypertrophy) or irregular skin, rotate sites or ask your provider about changing the injection site.

When to Seek Medical Help

  • Symptoms of severe hypoglycaemia (confusion, seizures, loss of consciousness).
  • Persistent high or low blood glucose despite dose adjustments.
  • Unexplained weight loss, vision changes, or new symptoms that could indicate complications.

Important: This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult your prescribing clinician or diabetes educator before starting, stopping, or changing the dose of Soliqua or any other medication.



Other Questions About Soliqua :

How does Soliqua combine insulin and GLP-1? Soliqua 100 33 insulin and glp1? Soliqua 100/33 clinical trial data? Generic soliqua? Samples of soliqua 100/33? Soliqua 100/33 initiation? About soliqua 100/33?